Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the upcoming Evercore ISI HealthconX Conference, November 28-30, 2023.

• Thursday, November 30^th, the Company will participate in a fireside chat at 7:55 am ET/4:55 am PT and also host investor meetings.

A live webcast of the fireside chat will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120404684/en/

The Alpine Immune Sciences Stock at the time of publication of the news with a raise of +4,49 % to 12,80USD on Lang & Schwarz stock exchange (20. November 2023, 22:30 Uhr).